Side-effects: latest news

Side-effects resources

  • What are the side-effects of post-exposure prophylaxis (PEP)?

    In the UK the recommended first-line PEP medications of emtricitabine/tenofovir and raltegravir are generally well tolerated by most people.Nonetheless, some people do have short-term problems with...

    From: Factsheets

    Information level Level 2
  • Talking to your doctor

    Taking antiretroviral therapy is a long-term commitment. At present, once you start the drugs, you are likely to be on them for the rest of your life. ...

    From: Booklets

    Information level Level 2
  • Antiretroviral drugs chart

    A one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions....

    From: Antiretroviral drugs chart

    Information level Level 1
  • Side-effects

    Many side-effects are the result of your body getting used to a new drug.Other medicines can be taken to help control side-effects.Possible side-effects should be taken...

    From: Factsheets

    Information level Level 2
  • Skin problems

    A rash can be a symptom of recent HIV infection. Other infections can also cause skin problems. They may also be a side-effect or allergic reaction to an anti-HIV drug. Allergic drug...

    From: Factsheets

    Information level Level 2
  • Multiple medications and drug interactions

    The more drugs you take, the greater the risk of drug interactions and side-effects. It’s important to tell your doctors and pharmacists about all the other medicines you take. An...

    From: Factsheets

    Information level Level 2
  • Lactic acidosis

    Lactic acidosis refers to a build-up of lactic acid in the blood.It is a rare but dangerous side-effect of some anti-HIV drugs – most of...

    From: Factsheets

    Information level Level 2
  • Pain

    Pain can cause emotional and mental health problems.Medication can be used in both the short and long term to control pain.Treating underlying medical problems may...

    From: Factsheets

    Information level Level 2
  • Neuropathy – nerve pain

    Peripheral neuropathy means damage to the nerves in the feet or hands.Symptoms can range from tingling to numbness to excruciating pain.There are many possible causes, including anti-HIV...

    From: Factsheets

    Information level Level 2
  • Hyperbilirubinaemia

    High levels of bilirubin in the body can be a side-effect of the anti-HIV drug atazanavir.It can make the skin or eyes more yellow, but...

    From: Factsheets

    Information level Level 2
  • Side-effects

    The booklet provides information about possible side-effects of HIV treatment. ...

    From: Booklets

    Information level Level 2
  • Nausea and vomiting

    Nausea and vomiting are possible side-effects of some HIV drugs.Most often, these side-effects will go away after a few weeks of taking the drug.Medicines called...

    From: Factsheets

    Information level Level 2
  • Changing HIV treatment

    Talk to your doctor if you are concerned about any side-effects you are experiencing.If you are having problems taking your HIV treatment, it’s important to be honest...

    From: Factsheets

    Information level Level 2
  • Diarrhoea

    Diarrhoea is common in people with HIV, particularly those with a low CD4 count.It can be caused by infection and is also a possible side-effect of some...

    From: Factsheets

    Information level Level 2
  • Side-effects checker

    A tool to help you talk to your healthcare team about any side-effects or symptoms that you have....

    From: Resources

  • Tiredness and fatigue

    Illnesses and drug side-effects can contribute to fatigue.People often report an increase in their energy levels after starting HIV treatment.A healthy balanced diet may help...

    From: Factsheets

    Information level Level 2
  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • Managing side-effects that interfere with eating

    Like all medicines, the drugs used to treat HIV can cause side-effects. These are most likely to occur when you first start taking a drug, but...

    From: Booklets

    Information level Level 2
  • Sleep

    Sleep is essential to physical and mental health.Anxiety, depression, drug or alcohol use, and illness can contribute to sleep problems.Simple lifestyle changes may be enough to...

    From: Factsheets

    Information level Level 2
  • Lipodystrophy

    Lipodystrophy is a side-effect of some older anti-HIV drugs which are now rarely used.Lipodystrophy includes both weight gain and weight loss.It is common for people...

    From: Factsheets

    Information level Level 2
  • Talking points: a checklist for you and your doctor

    Talking points is designed to help you talk to your doctor about HIV treatment....

    From: Resources

  • My drugs chart

    My drugs chart provides information on all the anti-HIV drugs currently licensed for use in Europe.Select your chosen drugs and drag them onto the area...

    From: My drugs chart

  • HIV treatment side-effects and mental health

    Some anti-HIV drugs can affect your emotional and mental health. Most notably, the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva, also in the combination pill, Atripla) has...

    From: Booklets

    Information level Level 2
  • HIV treatment in women

    The evidence available suggests that HIV treatment works well for women. Unless you are pregnant, the recommendations for HIV treatment are the same for both women and...

    From: Booklets

    Information level Level 2
  • Side-effects

    Like all medications, anti-HIV drugs can cause side-effects and these can be a reason why people don’t take their treatment properly. The risk of side-effects can vary between...

    From: Booklets

    Information level Level 2
  • Effect of genetic variation on side-effects of HIV drugs

    In addition to drug levels, the other major area of research interest in pharmacogenetics is the association of human genetic variation with the incidence or...

    From: HIV treatments directory

    Information level Level 4
  • Side-effects

    Information on the side-effects associated with anti-HIV treatments and other drugs, including advice on how to cope with them, and whether treatment should be stopped...

    From: HIV treatments directory

    Information level Level 4

Side-effects features

Side-effects in your own words

Side-effects news from aidsmap

More news

Side-effects news selected from other sources

  • Tenofovir Alafenamide Linked to Fanconi Syndrome

    This case study is presented as a caution to clinicians that tenofovir alafenamide can cause Franconi Syndrome.

    12 February 2019 | Infectious Disease Advisor
  • South Africa urgently needs an antiretroviral pregnancy registry

    With the dolutegravir roll-out around the corner, the time is now ripe for patients and activists to demand a prospective pregnancy registry for the whole of South Africa. Whether it is a new endeavour or piggy-backs on international efforts is a matter for debate, but it is the only way we can answer the question of dolutegravir’s safety with the minimum number of women being exposed to the drug. It’s the least that patients deserve.

    29 January 2019 | Spotlight
  • Six advantages of dolutegravir

    Dolutegravir is a critically important antiretroviral medicine that is set to become the backbone of South Africa and many other countries’ HIV programmes. While the drug has recently made headlines because of a potential safety risk, most of what we know about the medicine indicates that it represents an important improvement over existing medicines.

    28 January 2019 | Spotlight SA
  • South Africa: New safety concerns emerge on latest HIV wonder drug

    New safety concerns have emerged about the HIV drug dolutegravir, which the government plans to roll out in April.

    18 January 2019 | Business Day
  • Sleep Abnormalities Do Not Reverse After Discontinuing Efavirenz

    For patients with HIV receiving efavirenz-based therapy, sleep and neuropsychological abnormalities do not readily reverse after discontinuation of treatment, according to results published in HIV Clinical Trials.

    14 January 2019 | Infectious Disease Advisor
  • Top 10 HIV Clinical Developments of 2018

    It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

    20 December 2018 | The Body Pro
  • What triggered my heart attack?

    Jackie Morton, ex-Chair of the European AIDS Treatment Group, found her severe pain was due to a heart attack. Here she writes a detailed, dispassionate and scientific blog on the possible causes - and remedies.

    19 November 2018 | EATG
  • Cardiovascular Risk Unclear for HIV Patients on Dolutegravir

    Patients with HIV who switched to a dolutegravir-based regimen from a ritonavir-boosted protease inhibitor regimen experienced body mass gain and changes in biomarkers related to increased insulin resistance, according to a subanalysis of the NEAT 022 study.

    01 November 2018 | Medscape (requires free registration)
  • Dolutegravir Use During Pregnancy: What Are the Risks?

    Infectious Disease Advisor spoke to Rebecca M. Zash, MD, a co-investigator of the interim analysis by the Tsepamo Study in Botswana, which was published in the New England Journal of Medicine in July.

    22 October 2018 | Infectious Disease Advisor
  • Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

    Researchers found children of women whose ART regimen included efavirenz were 60 percent more likely to develop a neurological condition, such as microcephaly (small head), seizures (from a high fever or other cause) and eye abnormalities than children whose mothers took other ART medications.

    05 October 2018 | IDSA press release
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.